Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire

Research output: Contribution to journalArticle

Abstract

Objective: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. We sought to quantify autonomic symptom burden in SSc, and to define the characteristics of patients with SSc and autonomic dysfunction. Methods: Patients with SSc were consecutively recruited during routine clinical visits at the Johns Hopkins Scleroderma Center and asked to complete the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire, a validated tool to assess symptoms of autonomic dysfunction. We determined the relationship between various clinical and serological features of SSc and the total COMPASS-31 scores and domain-specific scores using the Student t test or Wilcoxon rank-sum test for dichotomous variables and linear regression analysis for continuous variables. Results: The study included 104 patients with SSc who completed the COMPASS-31 questionnaire. The mean COMPASS-31 score in this cohort was 24.9 ± 15.5, higher than COMPASS-31 scores from previously published healthy controls (8.9 ± 8.7). Compared to patients with mild or absent GI disease, patients with significant GI disease had higher scores across several subdomains of the COMPASS-31, including orthostatic intolerance (median 10.0 vs 0, p = 0.006) and secretomotor dysfunction (median 6.4 vs 4.3, p = 0.03). There was also a dose-response relationship between GI disease severity and autonomic symptom burden. Conclusion: Symptoms of autonomic dysfunction are common in SSc. Patients with more severe GI disease in SSc report more symptoms of dysautonomia across many facets of the autonomic nervous system.

Original languageEnglish (US)
Pages (from-to)1145-1152
Number of pages8
JournalJournal of Rheumatology
Volume45
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Systemic Scleroderma
Gastrointestinal Diseases
Nonparametric Statistics
Orthostatic Intolerance
Primary Dysautonomias
Gastrointestinal Motility
Surveys and Questionnaires
Autonomic Nervous System
Blood Vessels
Linear Models
Heart Rate
Regression Analysis
Students
Blood Pressure

Keywords

  • Autonomic dysfunction
  • Gastrointestinal tract
  • Neurologic manifestations
  • Self-assessment
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire. / Adler, Brittany; Russell, James W.; Hummers, Laura; McMahan, Zsuzsanna.

In: Journal of Rheumatology, Vol. 45, No. 8, 01.08.2018, p. 1145-1152.

Research output: Contribution to journalArticle

@article{cac41d7a5cd54429b0a13ccd411afda7,
title = "Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire",
abstract = "Objective: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. We sought to quantify autonomic symptom burden in SSc, and to define the characteristics of patients with SSc and autonomic dysfunction. Methods: Patients with SSc were consecutively recruited during routine clinical visits at the Johns Hopkins Scleroderma Center and asked to complete the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire, a validated tool to assess symptoms of autonomic dysfunction. We determined the relationship between various clinical and serological features of SSc and the total COMPASS-31 scores and domain-specific scores using the Student t test or Wilcoxon rank-sum test for dichotomous variables and linear regression analysis for continuous variables. Results: The study included 104 patients with SSc who completed the COMPASS-31 questionnaire. The mean COMPASS-31 score in this cohort was 24.9 ± 15.5, higher than COMPASS-31 scores from previously published healthy controls (8.9 ± 8.7). Compared to patients with mild or absent GI disease, patients with significant GI disease had higher scores across several subdomains of the COMPASS-31, including orthostatic intolerance (median 10.0 vs 0, p = 0.006) and secretomotor dysfunction (median 6.4 vs 4.3, p = 0.03). There was also a dose-response relationship between GI disease severity and autonomic symptom burden. Conclusion: Symptoms of autonomic dysfunction are common in SSc. Patients with more severe GI disease in SSc report more symptoms of dysautonomia across many facets of the autonomic nervous system.",
keywords = "Autonomic dysfunction, Gastrointestinal tract, Neurologic manifestations, Self-assessment, Systemic sclerosis",
author = "Brittany Adler and Russell, {James W.} and Laura Hummers and Zsuzsanna McMahan",
year = "2018",
month = "8",
day = "1",
doi = "10.3899/jrheum.170868",
language = "English (US)",
volume = "45",
pages = "1145--1152",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire

AU - Adler, Brittany

AU - Russell, James W.

AU - Hummers, Laura

AU - McMahan, Zsuzsanna

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. We sought to quantify autonomic symptom burden in SSc, and to define the characteristics of patients with SSc and autonomic dysfunction. Methods: Patients with SSc were consecutively recruited during routine clinical visits at the Johns Hopkins Scleroderma Center and asked to complete the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire, a validated tool to assess symptoms of autonomic dysfunction. We determined the relationship between various clinical and serological features of SSc and the total COMPASS-31 scores and domain-specific scores using the Student t test or Wilcoxon rank-sum test for dichotomous variables and linear regression analysis for continuous variables. Results: The study included 104 patients with SSc who completed the COMPASS-31 questionnaire. The mean COMPASS-31 score in this cohort was 24.9 ± 15.5, higher than COMPASS-31 scores from previously published healthy controls (8.9 ± 8.7). Compared to patients with mild or absent GI disease, patients with significant GI disease had higher scores across several subdomains of the COMPASS-31, including orthostatic intolerance (median 10.0 vs 0, p = 0.006) and secretomotor dysfunction (median 6.4 vs 4.3, p = 0.03). There was also a dose-response relationship between GI disease severity and autonomic symptom burden. Conclusion: Symptoms of autonomic dysfunction are common in SSc. Patients with more severe GI disease in SSc report more symptoms of dysautonomia across many facets of the autonomic nervous system.

AB - Objective: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) that can affect vascular tone, gastrointestinal (GI) motility, heart rate, and blood pressure control. We sought to quantify autonomic symptom burden in SSc, and to define the characteristics of patients with SSc and autonomic dysfunction. Methods: Patients with SSc were consecutively recruited during routine clinical visits at the Johns Hopkins Scleroderma Center and asked to complete the Composite Autonomic Symptom Score (COMPASS)-31 questionnaire, a validated tool to assess symptoms of autonomic dysfunction. We determined the relationship between various clinical and serological features of SSc and the total COMPASS-31 scores and domain-specific scores using the Student t test or Wilcoxon rank-sum test for dichotomous variables and linear regression analysis for continuous variables. Results: The study included 104 patients with SSc who completed the COMPASS-31 questionnaire. The mean COMPASS-31 score in this cohort was 24.9 ± 15.5, higher than COMPASS-31 scores from previously published healthy controls (8.9 ± 8.7). Compared to patients with mild or absent GI disease, patients with significant GI disease had higher scores across several subdomains of the COMPASS-31, including orthostatic intolerance (median 10.0 vs 0, p = 0.006) and secretomotor dysfunction (median 6.4 vs 4.3, p = 0.03). There was also a dose-response relationship between GI disease severity and autonomic symptom burden. Conclusion: Symptoms of autonomic dysfunction are common in SSc. Patients with more severe GI disease in SSc report more symptoms of dysautonomia across many facets of the autonomic nervous system.

KW - Autonomic dysfunction

KW - Gastrointestinal tract

KW - Neurologic manifestations

KW - Self-assessment

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85051750744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051750744&partnerID=8YFLogxK

U2 - 10.3899/jrheum.170868

DO - 10.3899/jrheum.170868

M3 - Article

VL - 45

SP - 1145

EP - 1152

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -